A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03794440 |
Recruitment Status : Unknown
Verified May 2020 by Innovent Biologics (Suzhou) Co. Ltd..
Recruitment status was: Active, not recruiting
First Posted : January 7, 2019
Last Update Posted : January 22, 2021
|
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Information provided by (Responsible Party):
Innovent Biologics (Suzhou) Co. Ltd.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | December 2022 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
July 21, 2021 | August 16, 2021 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):